Search

Displaying results 3601 - 3610 of 7284 in total
  1. Drug

    Surzetoclax

    go.drugbank.com/drugs/DB21698
    Investigational

    Surzetoclax has a monoisotopic molecular weight of 1038.41 Da. … Surzetoclax is a small molecule drug. The usage of the INN stem '-toclax' in the name indicates that Surzetoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor.

  2. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    [L43697] After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving … [L44483] Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.[L48385].

  3. Drug

    Hydroxyurea

    go.drugbank.com/drugs/DB01005
    ApprovedInvestigational

    [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. … Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928.

    Products: Hydroxycarbamid 1A Pharma 100 mg - Filmtabletten, Hydroxycarbamid 1A Pharma 1000 mg - Filmtabletten
  4. Drug

    Bicalutamide

    go.drugbank.com/drugs/DB01128
    ApprovedInvestigational

    It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: BICALUTAMID 1A PHARMA50MG, BICALUTAMID 1A PHARMA 50
  5. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from

  6. Drug

    Interferon alfa-2b

    go.drugbank.com/drugs/DB00105
    ApprovedInvestigational

    A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes.

    Mixtures: Intron A, Intron ASynonyms: Intron A, Intron A (Interferon α2b)
  7. Drug

    Elbimilast

    go.drugbank.com/drugs/DB20663
    Investigational

    Elbimilast has a monoisotopic molecular weight of 442.04 Da. … Elbimilast is a small molecule drug. The usage of the INN stem '-milast' in the name indicates that Elbimilast is a Phosphodiesterase-4 (PDE4) inhibitor.

  8. Drug

    Lixisenatide

    go.drugbank.com/drugs/DB09265
    ApprovedInvestigational

    [L764] Adlyxin recieved FDA approval July 28, 2016.[L763] … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM).

    Mixtures: Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen, SOLIQUA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100UNITS/ML + 50MCG/ML
  9. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. … Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond.

    Mixtures: FIBRASE SA
  10. Target

    Phospholipid-transporting ATPase IF

    go.drugbank.com/bio_entities/BE0021215
    TargetHumans

    Catalytic component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids, phosphatidylserines (PS) and phosphatidylethanolamines (PE), from

    Synonyms: P4-ATPase flippase complex alpha subunit ATP11B